术前放射外科治疗脑转移瘤切除:PROPS-BM多中心队列研究
PROPS-BM多中心队列纳入242例实体瘤脑转移患者共253个病灶,评估术前SRS后计划切除的结局与预后因素。1年与2年腔局部复发率分别为15%和17.9%,次全切除是局部复发的强独立预测因素(HR 9.1,P<.001)。1年与2年脑膜病发生率分别为6.1%和7.6%,任何级别不良放射效应分别为4.7%和6.8%,中位总生存16.9个月。
要点
- 术前SRS后2年腔局部复发率17.9%,次全切除者局部复发风险显著升高(HR 9.1)。
- 2年脑膜病发生率7.6%、任何级别不良放射效应6.8%,脑膜病以经典糖衣样型为主(68.4%)。
- 术后≥3级手术并发症发生率4.1%,中位总生存16.9个月、2年总生存率38.4%。
核心结论
- 这项多中心研究是迄今最大的术前SRS队列,证实单中心研究中的有利结局,尤其是较低的脑膜病和不良放射效应发生率,且未见过高的术后手术并发症风险。
- 次全切除虽不常见,但与显著更差的腔局部复发相关,有必要开展术前与术后SRS的随机对照试验。
研究设计与样本
- 来自5家机构的多中心队列研究(PROPS-BM),纳入实体瘤脑转移且至少1个病灶接受术前SRS并计划切除的患者。
- 共纳入242例患者、253个指标病灶;允许对同步未切除脑转移灶行SRS。
- 影像学脑膜病分为结节型或经典「糖衣样」型(cLMD)。
主要发现
- 62.4%患者为单发脑转移,93.7%接受全切除,98.8%接受单次分割SRS,中位剂量15 Gy,中位肿瘤体积9.9 cc。
- 1年和2年腔局部复发率分别为15%和17.9%;次全切除是局部复发的强独立预测因素(HR 9.1,P<.001)。
- 1年和2年脑膜病发生率分别为6.1%和7.6%,任何级别不良放射效应分别为4.7%和6.8%。
- 中位总生存16.9个月,2年总生存率38.4%;19例脑膜病患者中13例(68.4%)为cLMD。
- 242例中10例(4.1%)发生≥3级术后手术并发症。
关键数值与推荐
- 术前SRS多采用单次分割,中位剂量15 Gy,中位肿瘤体积9.9 cc(98.8%患者为单次分割)。
- 次全切除预测腔局部复发的HR为9.1(P<.001)。
临床怎么用
- 术前SRS可作为术后SRS的可行替代方案,兼具较低的脑膜病和不良放射效应风险,且术后手术并发症风险未明显增加。
- 应尽量实现全切除,因次全切除与显著更差的腔局部复发相关。
- 术前SRS后需关注脑膜病复发,尤其是经典糖衣样型。
局限性
- 为多中心队列研究而非随机对照试验,术前与术后SRS的比较尚需随机试验验证(目前正在设计)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Preoperative radiosurgery (SRS) is a feasible alternative to postoperative SRS, with potential benefits in adverse radiation effect (ARE) and leptomeningeal disease (LMD) relapse. However, previous studies are limited by small patient numbers and single-institution designs. Our aim was to evaluate preoperative SRS outcomes and prognostic factors from a large multicenter cohort (Preoperative Radiosurgery for Brain Metastases [PROPS-BM]). METHODS AND MATERIALS: Patients with brain metastases (BM) from solid cancers who had at least 1 lesion treated with preoperative SRS and underwent a planned resection were included from 5 institutions. SRS to synchronous intact BM was allowed. Radiographic meningeal disease (MD) was categorized as either nodular or classical "sugarcoating" (cLMD). RESULTS: The cohort included 242 patients with 253 index lesions. Most patients (62.4%) had a single BM, 93.7% underwent gross total resection, and 98.8% were treated with a single fraction to a median dose of 15 Gray to a median gross tumor volume of 9.9 cc. Cavity local recurrence (LR) rates at 1 and 2 years were 15% and 17.9%, respectively. Subtotal resection (STR) was a strong independent predictor of LR (hazard ratio, 9.1; P < .001). One and 2-year rates of MD were 6.1% and 7.6% and of any grade ARE were 4.7% and 6.8% , respectively. The median overall survival (OS) duration was 16.9 months and the 2-year OS rate was 38.4%. The majority of MD was cLMD (13 of 19 patients with MD; 68.4%). Of 242 patients, 10 (4.1%) experienced grade ≥3 postoperative surgical complications. CONCLUSIONS: To our knowledge, this multicenter study represents the largest cohort treated with preoperative SRS. The favorable outcomes previously demonstrated in single-institution studies, particularly the low rates of MD and ARE, are confirmed in this expanded multicenter analysis, without evidence of an excessive postoperative surgical complication risk. STR, though infrequent, is associated with significantly worse cavity LR. A randomized trial between preoperative and postoperative SRS is warranted and is currently being designed.
引用
- Prabhu RS, Dhakal R, Vaslow ZK, et al. Preoperative Radiosurgery for Resected Brain Metastases: The PROPS-BM Multicenter Cohort Study. Int J Radiat Oncol Biol Phys. 2021. PMID: 34058254. doi:10.1016/j.ijrobp.2021.05.124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。